LABU / LABD Ratio Anchored VWAP over /under LABU LONG

On the weekly chart a LABU / LABD ratio is plotted with anchored VWAP bands and a volume
profile overlaid. I wanted to analyze this to affirm the highest of prospects for the
Biotechnology sector for 2024. LABU is triple leveraged Up while LABD is the inverse Down.
A good unleveraged biotech ETF is XBI. The chart shows LABU in a VWAP band and breakout
through the hohg volume area and then over it beginning early November. Unusually high
relative volume and volatility ramped up about the same time.
I readily conclude that LABU is the buy right now with the ratio rising. It is a low beat ETF
with good range due to the leveraging and high forecasts for 2024. I will make buys on
LABU at regular intervals on a 60-120 minute time frame looking for the weekly lows.
I will set an alert for a falling ratio on the 3H to daily chart to assess should the supertrend
fade. I believe that this will be a safe low risk swing long trade.
profile overlaid. I wanted to analyze this to affirm the highest of prospects for the
Biotechnology sector for 2024. LABU is triple leveraged Up while LABD is the inverse Down.
A good unleveraged biotech ETF is XBI. The chart shows LABU in a VWAP band and breakout
through the hohg volume area and then over it beginning early November. Unusually high
relative volume and volatility ramped up about the same time.
I readily conclude that LABU is the buy right now with the ratio rising. It is a low beat ETF
with good range due to the leveraging and high forecasts for 2024. I will make buys on
LABU at regular intervals on a 60-120 minute time frame looking for the weekly lows.
I will set an alert for a falling ratio on the 3H to daily chart to assess should the supertrend
fade. I believe that this will be a safe low risk swing long trade.
註釋
It could end up making another falling wedge which remains to play out or not.交易進行
LABu up today and the ratio rises as expected.交易進行
Ratio is sideways at this time免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。